Research Paper Volume 13, Issue 22 pp 24815—24828
Atorvastatin combined with dexamethasone promote hematoma absorption in an optimized rat model of chronic subdural hematoma
Figure 7. Changes in the expression of inflammatory factors and angiogenic factors in different treatment groups after chronic subdural hematoma modeling. (A) Changes in the Ang-1/Ang-2 mRNA ratio in the hematoma capsule of different treatment group after modeling. (B) Changes in VEGF protein expression in the hematoma capsule of different treatment group after modeling. (C) Changes in MMP-9 protein expression in the hematoma capsule detected by ELISAs of different treatment group after modeling. (D) Changes in IL-6 protein expression in the hematoma capsule detected by ELISAs of different treatment group after modeling. (E) Changes in IL-8 protein expression in the hematoma capsule detected by ELISAs of different treatment group after modeling. (F) Changes in IL-10 protein expression in the hematoma capsule detected by ELISAs of different treatment group after modeling. * p < 0.05 compared with the control group, ** p < 0.01 compared with the control group, *** p < 0.001 compared with the control group; # p<0.05, compared with the single atorvastatin treatment group, ## p<0.01, compared with the single atorvastatin treatment group; † p<0.05, compared with the single dexamethasone treatment group; †† p<0.01, compared with the single dexamethasone treatment group.